TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02869139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentholated lip moisturizer and ice popsicle
Description: Mentholated package of measures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-mentholated lip moisturizer and ice popsicle
Description: Non-mentholated package of measures
Study: NCT03607084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Health Worker Program
Description: The intervention trains selected teachers to deliver health lessons to students, perform basic first aid, recognize common illnesses, refer student to skilled medical attention when needed. The intervention provides schools with basic medical supplies including pain relief medication, thermometers, bandages, antiseptics, and oral rehydration solution. Vitamin A supplementation and presumptive deworming medication are administered to students during biannual health screenings.
Study: NCT02421211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV)
Description: Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV)
Description: Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)
Description: Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)
Description: Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
Study: NCT01897389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
Study: NCT01978275

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plexolong 100, pajunk, germany
Description: nonstimulating catheter
Study: NCT01834300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised exercise training
Description: The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
Study: NCT03140696

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg Alone
Description: A chicken egg will be offered for 2 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg and ready to use supplementary food (RUSF)
Description: A chicken egg and ready to use supplementary food (RUSF) will be offered for 2 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg and breast milk
Description: A chicken egg and breast milk will be offered for 2 days
Study: NCT01834300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
Study: NCT01109160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Dihydrate
Description: Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis.~Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).
Study: NCT04599153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventriculoperitoneal shunt opening pressure setting
Description: The ventriculoperitoneal shunt (Strata®) opening pressure can be changed using a magnetic tool. The possible settings are 0.5, 1.0, 1.5, 2.0, 2.5 with a higher setting number corresponding to a higher opening pressure and less drainage through the shunt. All settings are used in routine clinical practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventriculoperitoneal shunt opening pressure setting
Description: The ventriculoperitoneal shunt (Strata®) opening pressure can be changed using a magnetic tool. The possible settings are 0.5, 1.0, 1.5, 2.0, 2.5 with a higher setting number corresponding to a higher opening pressure and less drainage through the shunt. All settings are used in routine clinical practice.
Study: NCT03134573

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaferon, BAY86-5046)
Description: Solution for injection

Intervention type: DEVICE
Intervention: Betaconnect auto-injector
Description: Auto-injector for application of Betaferon solution which automatically covers injection related data

Intervention type: DEVICE
Intervention: myBETAapp
Description: Medical device which can be connected with Betaconnect auto-injector and displays injection related data to patients and offers tracking of patient reported data at the wellness- tracker
Study: NCT02397499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202
Study: NCT01897389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: 1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: 1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: 1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
Study: NCT02314429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal ring releasing lactic acid (racemic mixture)
Study: NCT02201576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~3. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)
Study: NCT00419640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation with RA lead in LAS position
Description: Pacemaker implantation with RA lead placed in low atrial septal position
Study: NCT02201576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma exchanges and intravenous immunoglobulins
Description: 1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~3. oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)
Study: NCT03729440

Intervention type: BEHAVIORAL
Intervention: development of complications or not
Description: assessment of development of complications
Study: NCT03061643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel 40 mg/m2 IV every 2 weeks plus ADT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen-Deprivation Therapy (ADT)
Description: docetaxel 40 mg/m2 IV every 2 weeks plus ADT
Study: NCT02323815

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Small-Quantity Lipid-based nutrient supplement
Description: A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child's health and nutrition topics
Description: Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child's health and nutrition topics
Description: Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
Study: NCT00419640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation with RA lead in LAS position
Description: Pacemaker implantation with RA lead placed in low atrial septal position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation with RA lead in RAA position
Description: Pacemaker implantation with RA lead placed in right atrial appendage position
Study: NCT00471354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
Study: NCT03917888

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: lung ultrasound will be performed daily in mechanically ventilated patients after 48 hours of ventilation to screen for ventilator associated pneumonia
Study: NCT02786966

Intervention type: OTHER
Group type: OTHER
Intervention: Canadian C-Spine Rule
Description: Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
Study: NCT01481779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Administered by SC injection via a pen device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered by SC injection with a pen device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered by SC injection with a pen device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered by SC injection with a pen device.
Study: NCT02875600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutri Drink
Description: To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
Study: NCT01537796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person weight loss
Description: Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
Study: NCT00419640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation with RA lead in RAA position
Description: Pacemaker implantation with RA lead placed in right atrial appendage position
Study: NCT02785887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatrician review
Description: In addition to routine oncological care, patients will be reviewed by a geriatrician and may receive intervention if CGA deficits are found
Study: NCT00604474

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HiResolution Bionic Ear System (Cochlear Implant)
Description: Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
Study: NCT01537796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT weight loss
Description: Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
Study: NCT01090687

Intervention type: RADIATION
Intervention: computed tomography (CT scan)
Description: Subjects will undergo cone beam breast CT scan
Study: NCT01537796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIT-BT weight loss
Description: Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
Study: NCT01090687

Intervention type: DEVICE
Intervention: computed tomography (CT scan)
Description: Subjects will undergo cone beam breast CT scan
Study: NCT03899077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240mg daily for 6 months (i.e. 6 28-day cycles); oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial
Description: Leuprorelin acetate 45mg for 6 months; subcutaneous use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate 10.8 MG Subcutaneous Implant
Description: Goserelin acetate 10.8mg for 6 months; subcutaneous use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin Pamoate
Description: Triptorelin pamoate 22.5mg for 6 months; intramuscular use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix acetate
Description: Degarelix acetate 80mg for 6 months; subcutaneous use
Study: NCT03612440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: receive matching placebo (equal volum of normal saline)
Study: NCT03353896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wear novoTTF-200A
Description: Wear novoTTF-200A device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02753231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low physical activity program
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High physical activity program
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low and High physical activity program
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
Study: NCT02397499

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02027805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-Guard
Study: NCT02753231

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical activity program
Description: One Physical Education sessions / week
Study: NCT00395694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamictal
Description: anti-epileptic drug
Study: NCT00185458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG IUS
Description: LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
Study: NCT01395563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Description: strength training, high intensity, twice up to 3 times per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training
Description: strength training, high intensity, twice up to 3 times per week
Study: NCT01871662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Legalon® SIL (Silibinin)
Description: Silibinin 20 mg/Kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Legalon® SIL (Silibinin)
Description: Silibinin 20 mg/Kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa2b
Description: 1.5 µg/kg once-weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa2b
Description: 1.5 µg/kg once-weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: At weight-based dose 800-1400 mg/day (BID, OS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: At weight-based dose 800-1400 mg/day (BID, OS)
Study: NCT02643784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.
Study: NCT01029301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: EndyMed Pro System for Skin Tightening
Description: Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);
Study: NCT01871662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: At weight-based dose 800-1400 mg/day (BID, OS)
Study: NCT02627235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIAL
Description: The physical activity intervention is based on Social Cognitive Theory and includes feedback on physical activity progress via IVR system and monthly graphic-based feedback letters delivered in the mail. Messages will encourage incremental increases until national PA guidelines are reached and provide specific information on cancer risk reduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait List Control
Description: Access to DIAL intervention 12 weeks following baseline assessment.
Study: NCT03530852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relizorb
Description: Tube feeds run across device to digest fats.
Study: NCT03930563

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-beetroot juice supplementation
Description: Before administering beetroot juice to subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-beetroot juice supplementation
Description: Before administering beetroot juice to subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-beetroot juice supplementation
Description: Before administering beetroot juice to subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-beetroot juice supplementation
Description: After administering beetroot juice to subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-beetroot juice supplementation
Description: After administering beetroot juice to subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post-beetroot juice supplementation
Description: After administering beetroot juice to subjects.
Study: NCT01713764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: American Diabetes Association Diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness and Positive Affect Skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Positive Affect Skills